Immune Checkpoint Blockade in Cancer Therapy

Immunologic checkpoint blockade with antibodies that target cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death protein 1 pathway (PD-1/PD-L1) have demonstrated promise in a variety of malignancies. Ipilimumab (CTLA-4) and pembrolizumab (PD-1) are approved by the US Fo...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Journal of clinical oncology Ročník 33; číslo 17; s. 1974
Hlavní autoři: Postow, Michael A, Callahan, Margaret K, Wolchok, Jedd D
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 10.06.2015
Témata:
Antibodies, Monoclonal - pharmacology
Antibodies, Monoclonal, Humanized - pharmacology
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - pharmacology
Biomarkers, Tumor
CTLA-4 Antigen - antagonists & inhibitors
CTLA-4 Antigen - immunology
Drug Administration Schedule
Humans
Ipilimumab
Neoplasms - drug therapy
Neoplasms - immunology
Programmed Cell Death 1 Receptor - antagonists & inhibitors
Programmed Cell Death 1 Receptor - immunology
Treatment Outcome
ISSN:1527-7755, 1527-7755
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Immunologic checkpoint blockade with antibodies that target cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death protein 1 pathway (PD-1/PD-L1) have demonstrated promise in a variety of malignancies. Ipilimumab (CTLA-4) and pembrolizumab (PD-1) are approved by the US Food and Drug Administration for the treatment of advanced melanoma, and additional regulatory approvals are expected across the oncologic spectrum for a variety of other agents that target these pathways. Treatment with both CTLA-4 and PD-1/PD-L1 blockade is associated with a unique pattern of adverse events called immune-related adverse events, and occasionally, unusual kinetics of tumor response are seen. Combination approaches involving CTLA-4 and PD-1/PD-L1 blockade are being investigated to determine whether they enhance the efficacy of either approach alone. Principles learned during the development of CTLA-4 and PD-1/PD-L1 approaches will likely be used as new immunologic checkpoint blocking antibodies begin clinical investigation.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1527-7755
1527-7755
DOI:10.1200/JCO.2014.59.4358